JP2018502068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502068A5 JP2018502068A5 JP2017530141A JP2017530141A JP2018502068A5 JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5 JP 2017530141 A JP2017530141 A JP 2017530141A JP 2017530141 A JP2017530141 A JP 2017530141A JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fusion protein
- condition
- high affinity
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Division JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502068A JP2018502068A (ja) | 2018-01-25 |
| JP2018502068A5 true JP2018502068A5 (enExample) | 2018-12-13 |
| JP7095992B2 JP7095992B2 (ja) | 2022-07-05 |
Family
ID=56108081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530141A Active JP7095992B2 (ja) | 2014-12-08 | 2015-12-08 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (enExample) |
| EP (1) | EP3230311B1 (enExample) |
| JP (2) | JP7095992B2 (enExample) |
| KR (1) | KR102654033B1 (enExample) |
| CN (1) | CN107108718B (enExample) |
| AU (1) | AU2015360642B2 (enExample) |
| CA (1) | CA2968987C (enExample) |
| NZ (1) | NZ732073A (enExample) |
| RU (1) | RU2725807C2 (enExample) |
| SG (1) | SG11201704124YA (enExample) |
| WO (1) | WO2016094456A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| WO2016094456A1 (en) | 2014-12-08 | 2016-06-16 | 1Globe Health Institute Llc | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022004805A1 (ja) * | 2020-06-30 | 2022-01-06 | 株式会社ガイアバイオメディシン | Ｎｋ細胞と抗体との結合を安定化する方法、及びその利用 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| DK0826696T3 (da) * | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| KR101023367B1 (ko) * | 1998-08-11 | 2011-03-18 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| UA93662C2 (uk) * | 2000-12-07 | 2011-03-10 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет |
| ATE535258T1 (de) * | 2001-06-01 | 2011-12-15 | Cornell Res Foundation Inc | Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen |
| WO2004076621A2 (en) * | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co. Ltd. | Compositions of nucleic acids for treating and detecting influenza virus |
| WO2004108158A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
| JP4948174B2 (ja) * | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| ZA200606410B (en) * | 2004-02-16 | 2007-12-27 | Micromet Ag | Less immunogenic binding molecules |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| US20080219978A1 (en) * | 2007-01-23 | 2008-09-11 | Ellsworth Jeff L | Soluble FcgammaRIA and related methods |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| JP6147670B2 (ja) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 改善された半減期を有する修飾された抗体 |
| JP2015505843A (ja) * | 2011-12-15 | 2015-02-26 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
| MX353382B (es) * | 2012-03-01 | 2018-01-10 | Amgen Res Munich Gmbh | Moleculas de union polipeptido de larga duracion. |
| WO2016094456A1 (en) | 2014-12-08 | 2016-06-16 | 1Globe Health Institute Llc | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
-
2015
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113710707B (zh) | 结合于psma的重链抗体 | |
| JP2018502068A5 (enExample) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| Getts et al. | Have we overestimated the benefit of human (ized) antibodies? | |
| JP2020525032A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| JP2016513467A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JPWO2019175223A5 (enExample) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2013520984A5 (enExample) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| WO2022242703A1 (zh) | 抗msln抗体及其应用 | |
| RU2017124141A (ru) | Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение | |
| JP2020533965A5 (enExample) | ||
| JP7797203B2 (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| CN108276492A (zh) | 抗pd－l1单克隆抗体及其应用 | |
| CN108314734A (zh) | 抗pd－1单克隆抗体及其应用 |